A new antiretroviral HIV treatment, Trogarzo (ibalizumab-uiyk), has been approved by the FDA for patients with HIV who have not have success with past HIV medications.
Increasing awareness of and access to newer HIV testing options such as free or reduced price on home and self-tests and couples HIV testing and counseling can facilitate increased levels of consistent testing among young, Black MSM, and transgender women.
Bacterial vaginosis may cause an increased risk for HIV acquisition in women taking oral or injectable hormonal contraception.
Excessive alcohol consumption does not impact the decline of CD4 cell count in patients with HIV who have not undergone antiretroviral treatments.
Chronicity of depression is associated with increased likelihood of failure along the continuum of HIV care.
For young adults without known risk factors, a one-time routine HIV screen at 25 years would optimize clinical outcomes and be cost-effective.
One third of HIV patients in the United States remain unvaccinated against hepatitis B.
Post-seroconversion brain morphology can occur in HIV patients, but aviremia maintenance via cART can slow of prevent brain injuries.
A new report from the CDC finds that HIV is being diagnosed sooner after initial infection than in previous years.
Nivolumab treatment for non-small-cell lung cancer may induce successful depletion of HIV reservoir.
The decrease in HIV incidence in Uganda was facilitated by antiretroviral therapy, male circumcision, and adolescent abstinence.
More tests might be administered to transgender individuals who are female, black, or sex workers.
The dual combination of dolutegravir plus darunavir/ritonavir provided a simple and safe salvage therapy to suppress viral replication without metabolic impact in patients infected with HIV-1.
Hepatitis B and hepatitis C may increase mortality risks in HIV patients.
The Ohio Supreme Court has unanimously upheld the constitutionality of a law requiring HIV-infected individuals to tell their sexual partners of their illness.
The CDC revised its US Medical Eligibility Criteria for Contraceptive Use categorization for DMPA injection in women at high risk for HIV infection from US MEC category 1 to US MEC category 2.
Resistance to ART is threatening the recent gains of treatment in the rate of new HIV infections.
More than half of women receiving a new HIV diagnosis have already received this diagnosis in the past but are not undergoing HIV medical care.
Infection was diagnosed at an early stage for fewer males with infection attributed to heterosexual contact vs male-to-male sexual contact.
Virological response, efficacy, noninferiority, and tolerability were tested for bictegravir, emtricitabine, and tenofovir alafenamide in patients with HIV.
The HIV Medicine Association of the Infectious Disease Society of America recommends that people living with HIV be screened for pain and offered both nonpharmacologic and pharmacologic treatment options.
In 16 countries, notification rates for new HIV diagnoses in older adults increased significantly, clustering in central and eastern European countries.
Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide was well tolerated in children and maintained high virological suppression.
High-dose vitamin D supplements improve bone mineral density in youth with HIV.
Alternative treatments should be offered to pregnant women with HIV instead of tenofovir or emtricitabine.
Smartphone-based electronic reader reliable for point-of-care tests in HIV and T pallidum infectionsSeptember 15, 2017
The findings shed new light on the applicability of smartphone-based electronic readers in point-of-care testing.
Adherence decreased over time in adolescent MSM who participated in a 48-week HIV PrEP intervention.
Women with mental illness engage in significantly more sexually risky behaviors than men, and personality risk scores are a significant predictor of total sex acts for women but not men.
Rapid HIV testing offered in parallel to patient-clinician consultations increases the testing rate in the emergency department.
The new guidelines address the issue of how to manage pretreatment HIV drug resistance in countries where the prevalence of is 10% or higher.